Is Feel Free Energy Drink Addictive? Inside the Arizona Lawsuit Exposing Kratom Risks
By James H. Sterling
At the center of the Arizona litigation is the biological action of Mitragyna speciosa, a tropical tree indigenous to Southeast Asia. For centuries, laborers in Thailand and Malaysia chewed raw kratom leaves to stave off fatigue during grueling manual labor. In concentrated, processed extract forms, however, the plant behaves differently. Kratom leaves produce dozens of distinct chemical compounds, dominated by two primary alkaloids: mitragynine and 7-hydroxymitragynine.
Mitragynine acts as a partial agonist at human mu-opioid receptors. These are the identical neurological sites stimulated by morphine, oxycodone, and prescription painkillers. At low doses, kratom produces stimulant properties via adrenergic pathways, heightening alertness and physical energy. As dosage mounts, the opioid receptor activity dominates. It suppresses pain, dampens emotional anxiety, and induces systemic relaxation. Regular consumption prompts the brain to downregulate its internal receptor density, requiring progressively higher quantities to produce the original feeling.
When habitual consumers attempt to stop drinking the tonic, the physiological reaction closely mirrors opioid cessation. Users document profuse sweating, intractable insomnia, severe restlessness, muscle spasms, crippling gastrointestinal distress, and debilitating panic. Compounding the issue is the formula's inclusion of kava (Piper methysticum), which influences GABA receptors. The combination of these two botanicals produces a synergistic sedative effect that can mask early physical tolerance, lulling consumers into regular consumption long before they recognize physical addiction.
James Sterling reports on renewable energy developments, climate policy, ecological conservation, and green tech innovations around the globe.
